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Abstract 
Background: Pain management and safe use of analgesics is an important medical issue. Tramadol is an old analge‑
sic with controversial properties. Evaluation of worldwide scientific output on tramadol has not been explored. There‑
fore, the main objective of this study was to give a bibliometric overview of global research productivity on tramadol.
Methods: SciVerse Scopus was used to retrieve and quantitatively and qualitatively analyze worldwide publications 
on tramadol.
Results: A total of 2059 original and review research articles on tramadol were retrieved from Scopus. Forty‑six docu‑
ments (2.23 %) were published in Anesthesia and Analgesia Journal whereas 30 (1.46 %) were published in Arzneimittel 
Forschung Drug Research Journal. Retrieved tramadol documents were published from 71 countries and appeared 
in 160 peer reviewed journals. Although the United States of America (259; 12.86 %) had the largest contribution to 
tramadol publications; the contribution by other countries like Turkey (232; 11.27) India (189; 8.09 %) and Germany 
(176; 8.56 % was not far away from that of USA. The most productive institution was Grunenthal, Germany (47; 2.28 %) 
followed by Tehran University of Medical Sciences, Iran (29; 1.41 %), and, Ortho‑McNeil Pharmaceutical Incorporated, 
USA (25; 1.21 %). Of the 2059 documents, there were 370 documents about dependence. The leading institution in 
documents pertaining to tramadol dependence was Grunenthal GmbH (18; 4.86 %) followed by Ortho‑McNeil Phar‑
maceutical Incorporated (17; 4.59 %).
Conclusions: The current study showed that there is an obvious interest in tramadol research. More efforts are 
needed to clarify the abuse potential and safety profile of tramadol to help in determining the legal status of trama‑
dol. Collaboration among pharmaceutical industry, clinical researchers and academic institutions can improve 
research quantity and quality on tramadol.
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Background
Search for best methods of pain management is as old 
as mankind (Gildenberg 1997; Greenblatt et  al. 1997). 
However, only in the past several decades did research 
about pain management showed great momentum and 
became a cornerstone in the medical field. The initiation 
of several international peer reviewed journals special-
ized in the field of pain/anesthesia has contributed to 
this positive momentum in pain research. Furthermore, 
the discovery and development of potent and unique 
analgesics have also increased attention to pain research. 
No doubt that the increase in prevalence of chronic pain 
has also stimulated many pharmaceutical companies to 
search for new analgesic medications those bear ideal 
characteristics. Despite the ongoing research and devel-
opment in the field of pain, no ideal analgesic drug has 
been found yet. A study that discussed the characteristics 
of more than 50 analgesics introduced in the past 50 years 
concluded that despite intense research efforts, there is 
no real novel analgesic drug discovery and an ideal anal-
gesic is not yet available (Kissin 2010). In 1977, trama-
dol, a new and atypical opioid analgesic medication, was 
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introduced and marketed by the German pharmaceutical 
company, Grünenthal GmbH. Since that time, many arti-
cles have been published about tramadol and its unique 
pharmacology and toxicology. Tramadol is unique in that 
it affects serotonin and norepinephrine systems in addi-
tion to its weak μ-opioid receptor agonist activity (Dayer 
et al. 1994, 1997; Grond and Sablotzki 2004; Epstein et al. 
2006; Raffa 2008; Reeves and Burke 2008). Therefore, 
tramadol has dual mechanism of action; µ opioid ago-
nist and a serotonin/norepinephrine reuptake inhibitor 
(Raffa 2013; Vazzana et  al. 2015). That is why tramadol 
causes adverse effects pertaining to elevated brain sero-
tonin levels (serotonin syndrome) especially when co-
administered with selective serotonin reuptake inhibitors 
(SSRI) drug class (Nelson and Philbrick 2012; Beakley 
et  al. 2015). Another important pharmacological aspect 
of tramadol is its metabolism by CYP2D6 which exhib-
its wide polymorphism leading to variation in toxic and 
therapeutic effects of tramadol (Lassen et al. 2015; Ibra-
him et al. 2016).
The abuse potential of tramadol is still an ongoing 
controversy (Friderichs et  al. 1978; Murano et  al. 1978; 
Richter et al. 1985; Ehrenreich and Poser 1993; Liu et al. 
1999; Aknine et al. 2000; Yates et al. 2001; Brinker et al. 
2002; Ripamonti et al. 2004; Naslund and Dahlqvist 2003; 
Woody et al. 2003; Skipper et al. 2004; Soyka et al. 2004). 
Understanding progress made in pain management 
research in general and about tramadol in particular 
requires periodic assessment of how scientific research 
in this topic is advancing. Bibliometric analysis, a sta-
tistical method for literature evaluation, is commonly 
used for assessment of research activity in any particu-
lar filed (Wallin 2005). Several bibliometric studies on 
pain related topics have been recently published (Robert 
et  al. 2008a, b; Dubner 2009; Mogil et  al. 2009; Onyeka 
and Chukwuneke 2014). However, based on author’s best 
knowledge, no bibliometric analysis has been published 
about analgesic drugs, particularly about a controver-
sial medication like tramadol. In this study we planned 
to give a bibliometric overview of tramadol publications 
through analysis of temporal research productivity and 
analysis of highly cited articles in tramadol field. This 
study is important for those in the field of clinical phar-
macology and medicine since it will give them a compre-
hensive look on current research trends on tramadol and 
future status of pain management in general and role of 
tramadol in pain management guidelines.
Methods
In this study, traditional bibliometric indicators were 
applied and presented. Such indicators have been 
explained in previous studies by the same authors. 
Standard competition ranking (SCR) was used to rank 
productive journals, countries, authors and institutions. 
The h-index (Hirsch 2005) was used to assess quantity 
and quality of research productivity by authors, countries 
and institutions. The journal impact factor (IF) obtained 
from the Journal Citation Report (JCR; Web of Knowl-
edge) 2014 science edition by Thomson Reuters and 
the SCImago Journal Rank (SJR) indicator (available at: 
http://www.scimagojr.com/SCImagoJournalRank.pdf ) 
were used as a quality indicator for journal strength and 
reputation. The adjustment index (AI) was used to strat-
ify productivity with income and population size and 
was obtained using the following equation: “AI =  [total 
number of publications for the country/gross domestic 
product (GDP) per capita of the country] × 1000, where 
the GDP per capita =  GDP/population of the country” 
(Sweileh et  al. 2013; Zyoud et  al. 2014e, 2015a). In this 
study, the keyword entered into Scopus search engine 
was “tramadol” in the “Article Title”. All subject areas 
were selected and the time interval of the analysis was 
set up to December 31st, 2013. Analysis was restricted to 
original and review articles. Citation analysis was com-
pleted within 1 day on July 29th, 2015 to avoid bias due 
to daily in database update. The extracted data were tabu-
lated and analyzed according to the indicators found in 
previous bibliometric studies (Sweileh et al. 2014; Zyoud 
et al. 2014b, c, e, f, 2015a, d).
Results
A total of 2429 research articles on tramadol were 
retrieved. Of the 2429 articles, there were 1958 (80.61 %) 
original journal articles, 101 (4.16  %) review articles, 
146 (6.01 %) letters, 67 (2.76 %) conference papers, and 
157 (6.47  %) other types of publications such as edito-
rial, notes, book chapters, erratum and undefined. 
Analysis in this manuscript was based on 2059 docu-
ments that were original research articles and reviews. 
The 2059 articles were written in 23 different languages. 
The main language encountered was English (n = 1687; 
80.68 %) followed distantly by Turkish (n = 87; 4.16 %), 
Chinese (n  =  72; 3.44  %), German (n  =  62; 2.97  %), 
Spanish (n = 56; 2.68 %), French (n = 24; 1.15 %), Ital-
ian (n = 21; 1.00 %), and 16 other languages (82; 3.92 %). 
The number of published documents about trama-
dol in the past 5  years (2008–2013) has increased by 
approximately 15-folds compared with the time interval 
from 1978 to 1988 (Table 1). The first article on trama-
dol was published in 1978. Retrieved tramadol articles 
were published from 71 countries and appeared in 160 
peer reviewed journals. Top ten productive countries 
on tramadol research are shown in Table  2. Tramadol 
research and publications were produced by countries 
from different world regions and even from countries 
outside Europe and North America. Although the largest 
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number of articles about tramadol was produced by the 
USA (259; 12.58 %); the contribution by other countries 
like Turkey (232; 11.27 %), India (189; 8.09 %) and Ger-
many (176; 8.56  %) was not far away from that of the 
USA (Table  2). It is noteworthy that Turkey surpassed 
Germany and other European countries in tramadol 
research.
The total citations of retrieved articles was 36,275, with 
an average of 17.62 citations per article as recorded in 
Scopus on July 29th, 2015. The h-index of tramadol pub-
lications was 74. List of most commonly cited articles 
on tramadol is shown in Table 3 (Raffa et al. 1992, 1993; 
Vickers et  al. 1992; Lee et  al. 1993; Poulsen et  al. 1996; 
Harati et  al. 1998; Sindrup et  al. 1999; Scott and Perry 
2000; Xia et al. 2000; Grond and Sablotzki 2004). Those 
about the potential mechanism of action and potential 
role of tramadol in treatment of neuropathic pain were 
most commonly cited. Two of the top 10 cited articles 
were published from the same research group, the Raffa 
et  al., group present in the USA. Table  4 shows top 10 
productive journals involved in tramadol research. Forty-
six articles (2.24  %) were published in Anesthesia and 
Analgesia whereas 30 (1.46 %) were published in Arznei-
mittel Forschung: Drug Research. Of the top 10 journals, 
six were in the field of anesthesia and pain, three in the 
field of pharmacology, therapeutics and drug research 
and one in the field of clinical pharmacology and anes-
thesia. Of the top 10 journals, two were Turkish journals 
while the others were based either in USA or Europe. 
When the journals were screened for IF, three journals of 
the top productive ones were not listed in ISI JCR and the 
remaining were listed and had an IF <5.
Table 5 presents scientific subjects of the 2059 articles. 
As expected, the majority were in the field of medicine 
(1303; 63.38  %) followed by pharmacology/toxicology/
pharmaceutics (721; 35.07 %) and chemistry (189; 9.19 %). 
Of the 2059 documents, there were 370 documents about 
dependence. The leading institution in documents per-
taining to tramadol dependence was Grunenthal GmbH 
(18; 4.86  %) followed by Ortho-McNeil Pharmaceuti-
cal Incorporated (17; 4.59  %). Table  6 shows top 10 
highly productive institutions which published most 
about tramadol. The most productive institution was 
Grunenthal, Germany (47; 2.44  %) followed by Tehran 
University of Medical Sciences, Iran (25; 1.30  %), and, 
Ortho-McNeil Pharmaceutical Incorporated, USA (25; 
1.3 %). Table 7 presents the top 10 productive authors on 
about tramadol, along with their affiliations. Half of the 
top prolific authors were from USA and seven were affili-
ated with academic institutions.
Discussion
Evidence-based pain management requires exploration 
of efficacy and safety of various analgesics as presented 
in literature. Our study analyzed 2059 research arti-
cles retrieved from Scopus, a large databases equipped 
Table 1 Worldwide growth of tramadol research activity










Table 2 Top 10 countries in tramadol research
a Percentage of documents with international authors from the total number of documents for each country
SCR standard competition ranking, Q1–Q3 lower quartile–upper quartile














1st United States 259 (12.58) 9273 53 19 (9–46) 38.44 26 61 (23.55) 4.74
2nd Turkey 232 (11.27) 2067 24 3 (1–13) 8.91 4 8 (3.45) 22.00
3rd India 189 (8.09) 1019 16 2 (0–6) 5.39 5 8 (4.23) 115.85
4th Germany 176 (8.56) 5533 40 17 (6–37) 31.44 17 36 (20.45) 3.69
5th China 134 (6.51) 835 16 2 (0–7.25) 6.23 4 10 (7.64) 17.64
6th Iran 101 (4.90) 1094 18 5 (2–11.5) 10.83 4 8 (7.92) 19.08
7th Italy 99 (4.81) 1609 22 6 (1–11) 7.01 15 24 (24.24) 2.83
8th Spain 80 (3.89) 1112 22 8.5 (1–24) 13.90 14 29 (36.25) 2.64
9th United King‑
dom
64 (3.11) 2238 26 19.5 (6.25–41.5) 34.97 15 24 (37.50) 1.40
10th France 50 (2.43) 952 16 9 (2–20.25) 19.04 13 20 (40.00) 1.17
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with search options that facilitate citation and compara-
tive analysis (de Granda-Orive et  al. 2011). Scopus cov-
ers higher number of journals in different subject areas 
and allows citation analysis which made it very suitable 
for bibliometric analysis compared to other databases 
(Tadmouri and Bissar-Tadmouri 2004; Falagas et al. 2008; 
Kulkarni et al. 2009; de Granda-Orive et al. 2011).
Tramadol was developed in early 1960s by Grunenthal, 
a German pharmaceutical company. Tramadol entered 
the West German market in late 1970s with the trade 
name Tramal®. Approximately 20  years later, tramadol 
was introduced to the US market. Currently, tramadol is 
available in 100 countries under different trade names. 
Although tramadol is unique in having dual mechanism 
of action, its introduction to the worldwide market was 
slow and cautious. A possible reason for this slow intro-
duction was the uncertainty regarding safety and abuse 
potential. However, reports and clinical trials have shown 
that tramadol has lesser toxic profile and better tolerabil-
ity than oral traditional nonsteroidal anti-inflammatory 
drugs (NSAIDs) or commonly used opioids (Preston 
et  al. 1991; Adams et  al. 2006; Epstein et  al. 2006). A 
study carried out to compare the abuse potential among 
NSAIDs, codeine, placebo and tramadol has found that 
abuse potential for tramadol is significantly lower than 
that of codeine (Adams et al. 2006). On the other hand, 
reports about other serious side effects like seizure have 
been reported (Tobias 1997; Raffa and Stone 2008; Sen 
Table 3 Top 10 cited articles in tramadol-related research
SCR standard competition ranking
a Equal articles have the same ranking number and then a gap is left in the ranking numbers
SCRa Authors Journal Cited by
1st Raffa et al. (1992) Journal of Pharmacology and Experimental Therapeutics 802
2nd Harati et al. (1998) Neurology 416
3rd Grond and Sablotzki (2004) Clinical Pharmacokinetics 402
4th Lee et al. (1993) Drugs 375
5th Xia et al. (2000) Bulletin of Hunan Medical University 360
6th Scott and Perry (2000) Drugs 331
7th Raffa et al. (1993) Journal of Pharmacology and Experimental Therapeutics 325
8th Vickers et al. (1992) Anaesthesia 292
9th Poulsen et al. (1996) Clinical Pharmacology and Therapeutics 290
10th Sindrup et al. (1999) Pain 273
Table 4 Top 10 journals in  which tramadol-related docu-
ments were published
SCR standard competition ranking, IF impact factor, SJR standard journal 
ranking, N/A not available
a Equal journals have the same ranking number and then a gap is left in the 
ranking numbers
SCRa Journal N (%)
N = 2059
IF SJR
1st Anesthesia and Analgesia 46 (2.23) 3.472 1.50
2nd Arzneimittel Forschung: Drug Research 30 (1.46) 0.701 0.25
2nd Agri: The Journal of The Turkish Society of 
Algology
30 (1.46) N/A 0.21
4th British Journal of Anaesthesia 28 (1.36) 4.853 1.84
4th European Journal of Pharmacology 28 (1.36) 2.532 0.87
6th European Journal of Anaesthesiology 27 (1.31) 2.942 0.96
7th Paediatric Anaesthesia 19 (0.92) 1.850 0.84
7th Journal of Anaesthesiology Clinical 
Pharmacology
19 (0.92) N/A 0.30
9th Clinical Therapeutics 18 (0.87) 2.731 0.80
9th European Journal of Clinical Pharmacol-
ogy
18 (0.87) 2.966 1.03
9th Egyptian Journal of Anaesthesia 18 (0.87) N/A 0.15
Table 5 Top 10 subject fields in  tramadol-related docu-
ments
SCR standard competition ranking, USA United States of America
a Equal research areas have the same ranking number and then a gap is left in 
the ranking numbers
b The total % exceeds 100 % because of overlap among subjects
SCRa Subject area N (%)b
N = 2059
1st Medicine 1303 (63.38)
2nd Pharmacology, toxicology and pharmaceutics 721 (35.02)
2nd Chemistry 189 (9.18)
4th Biochemistry, genetics and molecular biology 177 (8.60)
5th Neuroscience 132 (6.41)
6th Veterinary 119 (5.78)
7th Environmental science 46 (2.23)
8th Psychology 42 (2.04)
9th Agricultural and biological sciences 30 (1.46)
9th Dentistry 30 (1.46)
9th Nursing 30 (1.46)
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et al. 2009; Singh et al. 2009; Talaie et al. 2009; Taghad-
dosinejad et al. 2011; Yarkan Uysal et al. 2011; Boostani 
and Derakhshan 2012; Mehrpour 2013).
In our study, bibliometric techniques were applied to 
give an overview on worldwide published research on 
tramadol. The first publication about tramadol appeared 
in 1978 followed by rapid increase, particularly after 
1995 which coincide with the year of introduction in the 
US market. The first article about tramadol as analgesic 
was published by Rost, A., Schenck, E.G. in Arzneimit-
tel-Forschung/Drug Research in 1978 as a comparative 
clinical study (Rost and Schenck 1978). The discovery 
and identification of tramadol and its unique mechanism 
of action lead to the development of a newer tramadol-
like agent named tapentadol which is currently available 
in the market and promoted to have better safety profile 
than tramadol (Giorgi et al. 2012; Mercadante et al. 2012, 
2013; Cepeda et  al. 2013; Gohler et  al. 2013; Lee et  al. 
2013; Schwittay et al. 2013; Singh et al. 2013; Fejos et al. 
2014).
An average of 17.62 (median =  6) citations per arti-
cle was obtained in this study. This finding means that 
tramadol is an interesting topic for scientific research 
community. Furthermore, the fact that the top 10 pro-
ductive countries and top 10 productive institutions 
in tramadol research included countries and institutes 
outside the Americas and Europe suggest that tramadol 
research is of interest to many nations. It was obvious 
that non-academic institutions, particularly pharma-
ceutical companies, were involved heavily in tramadol 
Table 6 Top 10 productive institution in tramadol-related research
SCR standard competition ranking, USA United States of America
a Equal institutions have the same ranking number and then a gap is left in the ranking numbers
SCRa Institute N (%)
N = 2059 (100 %)
Affiliation of the institute
1st Grunenthal GmbH 47 (2.28) Germany
2nd Tehran University of Medical Sciences 29 (1.41) Iran
3rd Ortho‑McNeil Pharmaceutical Incorporated 25 (1.21) USA
4th Çukurova Üniversitesi 24 (1.17) Turkey
5th R. W. Johnson Pharmaceutical Research Institute 17 (0.83) USA
6th Universidade de Sao Paulo 16 (0.78) Brazil
7th University of Tennessee, Knoxville 13 (0.63) USA
8th Universität Bonn 12 (0.58) Germany
8th Università degli Studi di Roma La Sapienza 12 (0.58) Italy
8th Poznan University of Medical Sciences 12 (0.58) Poland
8th Bethune International Peace Hospital of the PLA 12 (0.58) China
Table 7 Top 10 authors in tramadol research
SCR standard competition ranking, USA United States of America
a Equal authors have the same ranking number and then a gap is left in the ranking numbers
SCRa Author name Total number of articles Affiliation Country
1st R. B. Raffa 18 Temple University, School of Pharmacy, Philadelphia USA
2nd M. Giorgi 16 University of Pisa, Department of Veterinary Clinical Sciences, Pisa Italy
3rd M. Kamin 15 Ortho Biotech Products, L.P., Bridgewater USA
3rd N. R. Rosenthal 15 Ortho‑McNeil Pharmaceutical Incorporated, Raritan USA
5th S. K. Cox 14 University of Tennessee, Knoxville, Department of Biomedical and Diagnostic Sciences, 
Knoxville
USA
6th Y. Gunes 13 Cukurova University, Department of Anesthesiology, Adana Turkey
6th D. Jordan 13 Ortho‑McNeil Pharmaceutical Incorporated, Raritan USA
6th D. Ozcengiz 13 Cukurova University, Department of Anesthesiology, Adana Turkey
9th G. Saccomanni 12 Universita di Pisa, Dipartimento di Farmacia, Pisa Italy
9th K. Minami 12 Emergency Life‑Saving Technique Academy of Tokyo, Hachioji Japan
9th G. Isik 12 Çukurova University, Faculty of Medicine, Department of Anesthesiology, Adana Turkey
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research for human or veterinary use (Wu et  al. 2001; 
Teppema et al. 2003; Giorgi et al. 2009a, b). In addition, 
research about tramadol and its potential use in prema-
ture ejaculation gave further momentum to tramadol 
research (Safarinejad and Hosseini 2006; Salem et  al. 
2008; Bar-Or et al. 2012). At the official level, research 
interest in tramadol was motivated by the debate about 
the legal status and whether to schedule or un-schedule 
tramadol. In Sweden and in several states in the USA, 
including New York, Arkansas, Illinois, Kentucky, Mis-
sissippi, North Dakota, Oklahoma, Tennessee, Wyo-
ming, and West Virginia have categorized tramadol as 
a schedule IV controlled substance. In most countries of 
the world, the legal status of tramadol is currently under 
re-evaluation.
Finally, the authors believe that this study, like all other 
bibliometric studies, has few limitations that have been 
explained in previous bibliometric studies (Li et al. 2011; 
Sweileh et al. 2013; Zyoud et al. 2014a, d, 2015b, c; Zyoud 
2015). Such limitations include the use of Scopus data-
base; the use of “tramadol” word as a title keyword in the 
search engine; and the restriction of analysis to original 
articles and article reviews. However, despite all this, the 
current study will be of great value for people in pain 
management policy and those involved in research per-
taining to analgesia.
Conclusions
Tramadol is an analgesic with controversial properties 
which made it an appealing topic for researchers from 
different scientific disciplines. Research output about 
tramadol was not confined to particular country. More 
research efforts are needed to shed light on the abuse 
potential and the non-analgesic therapeutic benefits of 
tramadol. Research activity about tramadol needs to 
be directed toward minimizing its side effects. Such 
research activity can be achieved through collaboration 
among people in pharmaceutical industry, clinical prac-
tice and academic institutions.
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